Pirfenidone Use Facts in Fibrotic Diseases: What Do We Know So Far?
- Aldo Torre-Delgadillo,
- Froylan David Martinez-Sanchez,
- Sofía Narvaez-Chávez,
- Mariana Herrera-Islas,
- Carlos Aguilar-Salinas,
- Jacqueline Córdova-Gallardo
Aldo Torre-Delgadillo
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Author ProfileFroylan David Martinez-Sanchez
Hospital General Dr Manuel Gea Gonzalez
Author ProfileSofía Narvaez-Chávez
Hospital General Dr Manuel Gea Gonzalez
Author ProfileMariana Herrera-Islas
Hospital General Dr Manuel Gea Gonzalez
Author ProfileCarlos Aguilar-Salinas
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Author ProfileAbstract
Pirfenidone has evinced noteworthy anti-inflammatory and antifibrotic
efficacy in both animal models and in some clinical trials. Its
pronounced potential for antifibrotic activity makes pirfenidone a
compelling prospect for the treatment of various fibrotic diseases.
Pirfenidone has several pleiotropic and anti-inflammatory mechanism of
action through different molecular pathways. Consequently, it attenuates
multiple inflammatory processes, including the secretion of
pro-inflammatory cytokines, apoptosis, and fibroblast activation.
Extensively studied for idiopathic pulmonary fibrosis, pirfenidone has
exhibited a favorable impact, and represents part of the current
treatment for this disease. In similar fibrotic diseases such as
interstitial lung disease, myocardial fibrosis, glomerulopathies,
aberrant skin scarring, chronic liver disease, and other fibrotic
disorders, pirfenidone seems to exert a beneficial effect. Given the
growing incidence of chronic fibrotic conditions, pirfenidone emerges as
a potential therapeutic option for the management of these patients.
Nonetheless, more clinical trials are needed to confirm its therapeutic
effect. In this review, we aim to expose the current evidence of
pirfenidone's effect in several fibrotic diseases.05 Feb 2024Submitted to Immunity, Inflammation and Disease 22 Feb 2024Reviewer(s) Assigned
19 May 2024Review(s) Completed, Editorial Evaluation Pending
20 May 2024Editorial Decision: Revise Major
28 May 20241st Revision Received
29 May 2024Submission Checks Completed
29 May 2024Assigned to Editor
29 May 2024Review(s) Completed, Editorial Evaluation Pending
19 Jun 2024Editorial Decision: Accept